This strategy may also be promise for the treatment of other types of cancer characterized by frequent amplification of TBC1D31 (> 50%; Figure S1d, Supporting Information), such as uveal melanoma, ovarian cancer, and uterine carcinosarcoma. The gene discussed is TBC1D31; the disease is ovarian carcinoma.